Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Myosin modulators move forward with FDA approval of mavacamten

The US FDA recently approved mavacamten, a first-in-class myosin modulator, for obstructive hypertrophic cardiomyopathy. By targeting actin mechanobiology, myosin modulators are emerging as important medicines in cardiology.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Proposed mechanism of action for mavacamten.

References

  1. Ommen, S. R. & Semsarian, C. Lancet 398, 2102–2108 (2021).

    Article  Google Scholar 

  2. Marian, A. J. & Braunwald, E. Circ. Res. 121, 749–770 (2017).

    CAS  Article  Google Scholar 

  3. Masri, A. & Olivotto, I. J. Am. Heart Assoc. 11, e024656 (2022).

    Article  Google Scholar 

  4. Day, S. M., Tardiff, J. C. & Ostap, E. M. J. Clin. Invest. 132, e148557 (2022).

    CAS  Article  Google Scholar 

  5. Green, E. M. et al. Science 351, 617–621 (2016).

    CAS  Article  Google Scholar 

  6. Anderson, R. L. et al. Proc. Natl Acad. Sci. USA 115, E8143–E8152 (2018).

    CAS  Article  Google Scholar 

  7. Rohde, J. A., Roopnarine, O., Thomas, D. D. & Muretta, J. M. Proc. Natl Acad. Sci. USA 115, E7486–E7494 (2018).

    CAS  Article  Google Scholar 

  8. Lee, K. H. et al. Proc. Natl Acad. Sci. USA 115, E1991–E2000 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Olivotto, I. et al. Lancet 396, 759–769 (2020).

    CAS  Article  Google Scholar 

  10. Spertus, J. A. et al. Lancet 397, 2467–2475 (2021).

    CAS  Article  Google Scholar 

  11. Hegde, S. M. et al. J. Am. Coll. Cardiol. 78, 2518–2532 (2021).

    CAS  Article  Google Scholar 

  12. Kumbhani, D. J. American College of Cardiology Meeting https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/04/01/02/42/VALOR-HCM (2022).

  13. Ho, C. Y. et al. J. Am. Coll. Cardiol. 75, 2649–2660 (2020).

    CAS  Article  Google Scholar 

  14. Chuang, C. et al. J. Med. Chem. 64, 14142–14152 (2021).

    CAS  Article  Google Scholar 

  15. Teerlink, J. R. et al. N. Engl. J. Med. 384, 105–116 (2021).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

A.C.C. was supported by NIH Medical Scientist Training Program Training Grant T32GM007739 and an American Heart Association Predoctoral Fellowship.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Alfred C. Chin or Sharlene M. Day.

Ethics declarations

Competing interests

S.M.D. receives research funding from Bristol Myers Squibb, consults for Tenaya Therapeutics and Pfizer, and is on the data monitoring board for Cytokinetics. A.C.C. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chin, A.C., Day, S.M. Myosin modulators move forward with FDA approval of mavacamten. Nat Cardiovasc Res 1, 595–596 (2022). https://doi.org/10.1038/s44161-022-00093-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-022-00093-x

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing